Sorry, you need to enable JavaScript to visit this website.

Internal Medicine Areas of Interest

IMPORTANT: Pfizer has implemented application windows for unsolicited requests. Please click here to view the Application and Batched Review Cycles.

Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. A formal notification regarding the status of your application will be sent once a decision is reached. Pfizer support will only be extended upon the execution of a research agreement. For any questions, please send an email to [email protected].

  • *Proposals accepted if outside of competitive grant program submission window*

    Research areas to be considered for Pfizer support include:

    • Evidence generation in Understanding Cachexia/Unintentional Weight Loss in Cancer or Heart Failure
    • Role of GDF-15/GFRAL Pathway in Cancer or Heart Failure
    • GDF-15/GFRAL Biology
    • Natural History (longitudinal) studies specifically related to cachexia/weight loss and/or heart failure


    We are not currently accepting proposals focusing on:

    • Studies involving investigational products
    • Any clinical or pre-clinical study involving the use of therapeutics, including GDF-15RA/GFRAL agents
    • Studies requesting use of Pfizer investigational drugs/pure compound
    • Retrospective database analysis of a specific drug
    • Highly invasive studies and studies that may have an ethical concern
    • Replication of existing studies (i.e., lack of innovation)
    • Pharmacoeconomic analyses

  • Research areas to be considered for Pfizer support include: Coming Soon!

  • Research areas to be considered for Pfizer support include:

    • Research on the therapeutic application of an oral CGRP receptor antagonist, rimegepant, in migraine, headache, and other diseases where CGRP antagonism may be of clinical benefit
    • Research on Migraine headache (general): Impact on quality of life and patient reported outcomes; development of clinical tools/methods for monitoring/improving patient care and treatment outcomes (proposals may include clinical or real-world evidence research, as well as other appropriate methodologies for the proposed research)
    • Research regarding health disparities associated with migraine

    Out of scope:

    • Head-to-head/comparative studies
    • Protocols which request placebo formations
    • Pediatric investigations
    • Studies that overlap with ongoing clinical research activities or other ISRs

  • Research areas to be considered for Pfizer support include but not limited to:

    • Research on the therapeutic application of an intranasal CGRP receptor antagonist, zavegepant, in migraine, headache, and other diseases (including comorbidities) where CGRP antagonism may be of clinical benefit
    • Research on the effectiveness of zavegepant in non-outpatient care settings
    • Research of zavegepant on the impact of quality of life and patient reported outcomes (proposals may include clinical or real-world evidence research, as well as other appropriate methodologies for the proposed research)

     

    Out of scope:

    • Head-to-head/comparative studies
    • Protocols which request placebo formations
    • Pediatric investigations
    • Studies that overlap with ongoing clinical research activities or other ISRs
    • Ex-US submissions (only submissions within the United States will be considered)
    1. Evidence generation of optimal management of NASH in various populations:
      1. NASH in non-obese patients, lean NASH patients
      2. NASH in patients with obesity
      3. NASH in patients with type 2 diabetes
      4. NASH in patients with elevated risk of CVD
      5. NASH in patients with metabolic and chronic diseases
    2. Improving NASH models of care in populations: Role of non-invasive diagnostic tools
    3. Evaluation of circulating biomarkers as predictors of NAFLD and NASH
    4. Validation of ultrasound or elastography to detect early cirrhosis in NASH patients
    5. Evaluating NASH progression or regression using non-biopsy outcome measures
    6. Understanding liver outcomes by stage of NASH with or without intervention with a breakdown by patients who resolve NASH, improve fibrosis or both

  • *Proposals accepted if outside of competitive grant program submission window*

    Research areas to be considered for Pfizer support include:

    • Pathophysiology and biology of overweight and obesity
    • Understanding Obesity as a disease
    • Utilizing retrospective databases, generate evidence of optimal management of obesity and co-existing comorbid conditions


    We are not currently accepting proposals focusing on:

    • Studies involving investigational products
    • Any clinical or pre-clinical study involving the use of therapeutics, including GLP-1 RA and/or anti-obesity drugs
    • Studies requesting use of Pfizer investigational drugs/pure compound
    • Retrospective database analysis of a specific drug; analysis of a drug class (i.e. GLP-1 RA class) is permissible
    • Highly invasive studies and studies that may have an ethical concern
    • Replication of existing studies (i.e., lack of innovation)
    • Pharmacoeconomic analyses